Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Non-Current Assets (2016 - 2025)

Gsk has reported Non-Current Assets over the past 10 years, most recently at $58.0 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $58.0 billion for Q4 2025, up 6.42% from a year ago — trailing twelve months through Dec 2025 was $58.0 billion (up 6.42% YoY), and the annual figure for FY2025 was $58.0 billion, up 6.42%.
  • Non-Current Assets for Q4 2025 was $58.0 billion at Gsk, up from $54.5 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for GLAXF hit a ceiling of $81.5 billion in Q4 2021 and a floor of $46.2 billion in Q4 2022.
  • Median Non-Current Assets over the past 5 years was $54.5 billion (2024), compared with a mean of $58.1 billion.
  • Biggest five-year swings in Non-Current Assets: tumbled 43.3% in 2022 and later increased 8.81% in 2024.
  • Gsk's Non-Current Assets stood at $81.5 billion in 2021, then tumbled by 43.3% to $46.2 billion in 2022, then increased by 8.46% to $50.1 billion in 2023, then rose by 8.81% to $54.5 billion in 2024, then rose by 6.42% to $58.0 billion in 2025.
  • The last three reported values for Non-Current Assets were $58.0 billion (Q4 2025), $54.5 billion (Q4 2024), and $50.1 billion (Q4 2023) per Business Quant data.